Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Medtronic research highlights benefits of cardiac monitor device

Medtronic research highlights benefits of cardiac monitor device

1st October 2010

Medtronic has made new study data available which demonstrates the benefits of its Reveal Plus implantable cardiac monitor technology in assessing heart disease patients.

The company has published findings from the Carisma trial, which is the first study to document the incidence and prognostic significance of arrhythmias among certain acute myocardial infarction patients, as monitored by an insertable cardiac monitor.

Arrhythmias were detected among 46 per cent of the patients monitored, with the condition proving to be asymptomatic in 86 per cent of cases.

Figures of this kind have previously been unobtainable due to a lack of clinically-validated measurement tools.

Pat Mackin, president of the cardiac rhythm disease management business and senior vice-president at Medtronic, said: "Our Reveal family of devices can provide special monitoring information for physicians managing patients at risk for arrhythmias, providing more information to help determine the most appropriate treatment option."

Last week, the company was granted CE Mark accreditation for its Deep Brain Stimulation therapy to be used among refractory epilepsy sufferers, based on positive data from a clinical study.ADNFCR-8000103-ID-800094663-ADNFCR

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.